Updated October 6, 2026 with pelacarsen’s Lp(a)HORIZON topline results.
Four medications in development target high Lp(a): pelacarsen, olpasiran, lepodisiran, and muvalaplin. But lowering Lp(a) doesn’t guarantee fewer heart attacks. On September 4, 2026, Novartis reported that pelacarsen’s Lp(a)HORIZON trial missed its primary cardiovascular endpoint, despite lowering Lp(a).
Lp(a) is the strongest genetic risk factor for heart disease. About 20% of people have elevated levels, and current medications (statins, ezetimibe) do not lower it. The remaining trials will test whether other Lp(a)-lowering drugs prevent heart attacks and strokes.
In this post, we’ll walk through each of the four drugs (pelacarsen, olpasiran, lepodisiran, and muvalaplin), the trial behind each one, its timeline, and what the data shows so far.
Diagram of various potential approaches to lowering Lp(a).
Pelacarsen (Novartis)
Pelacarsen is an antisense oligonucleotide (ASO) that blocks production of apolipoprotein(a) in the liver. It is given as a monthly subcutaneous injection (80 mg).
Phase 2 trials showed pelacarsen lowered Lp(a) by up to 80%. The Phase 3 Lp(a)HORIZON trial enrolled 8,323 people with cardiovascular disease and Lp(a) of at least 70 mg/dL.
Novartis’s September 4 announcement reported that the trial missed its primary endpoint: reducing cardiovascular death, heart attack, stroke, or urgent procedures to restore blood flow to the heart compared with placebo. The announcement didn’t include a hazard ratio or confidence interval. Novartis plans to present the data at an upcoming medical congress.
Olpasiran (Amgen)
Olpasiran is a small interfering RNA (siRNA) therapy that silences the LPA gene in the liver. It is given as an injection every 12 weeks.
The Phase 3 trial started in December 2022 and enrolled roughly 7,000 patients with established ASCVD and Lp(a) of at least 200 nmol/L. Estimated completion is December 2026. In the earlier Phase 2 OCEAN(a)-DOSE trial, olpasiran lowered Lp(a) by more than 95% at the highest dose.
Lepodisiran (Eli Lilly)
Lepodisiran is an siRNA therapy targeting apolipoprotein(a). Phase 2 data suggests dosing may be as infrequent as every 6 months.
The ACCLAIM-Lp(a) trial started in 2024 and is still enrolling. It plans to randomize 16,700 patients, making it the largest of the four trials. It enrolls both secondary prevention (established ASCVD) and primary prevention (high-risk first-event) patients. Estimated completion is 2029. Lepodisiran lowered Lp(a) by 93.9% in the Phase 2 ALPACA trial
Muvalaplin (Eli Lilly)
Muvalaplin is the only oral drug in the group. It is a small molecule that blocks the assembly of the Lp(a) particle by disrupting the bond between apolipoprotein(a) and apolipoprotein B. Muvalaplin lowered Lp(a) by 47-86%, depending on the dose, in KRAKEN (Phase 2 trial). Lilly’s Phase 3 cardiovascular outcomes trial is now enrolling, with results expected later this decade.
Lp(a) lowering drugs compared
| Drug | Sponsor | Modality | Dosing | Outcomes trial | Started | Results / expected timing |
|---|---|---|---|---|---|---|
| Pelacarsen | Novartis / Ionis | Antisense oligonucleotide | Monthly injection | Lp(a) HORIZON (n=8,323) | Dec 2019 | Sep 4, 2026: primary endpoint not met |
| Olpasiran | Amgen | siRNA | Injection every 12 weeks | OCEAN(a)-Outcomes (n=~7,000) | Dec 2022 | Dec 2026 |
| Lepodisiran | Eli Lilly | siRNA | Injection every 6 months | ACCLAIM-Lp(a) (n=16,700) | 2024 | 2029 |
| Muvalaplin | Eli Lilly | Oral small molecule | Daily pill | Phase 3 (enrolling) | 2025 | Late decade |
When will Lp(a) drugs be available?
Pelacarsen remains investigational after missing its primary endpoint. Novartis hasn’t committed to an approval timeline. Trial completion dates for the other drugs aren’t pharmacy availability dates; they still need results and regulatory review.
In the meantime, the 2026 AHA/ACC guidelines recommend that every adult test their Lp(a) at least once. Our Lipoprotein(a) page covers the normal ranges and how to test.
Get your free 30-day heart health guide
Evidence-based steps to optimize your heart health.